A Prospective, Single-arm, Open-label, Non-interventional, Multicenter, Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Advanced or Metastatic Kidney Cancer, Cervical Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer or Glioblastoma Multiforme.

This is a prospective, single-arm, open-label, non-interventional, multicenter, post-marketing surveillance to assess the safety and effectiveness of Zirabev(Bevacizumab biosimilar) in domestic patients with non-small cell lung cancer, metastatic colorectal cancer, metastatic breast cancer, advanced or metastatic kidney cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or glioblastoma multiforme.

Start Date16 May 2025

Sponsor / Collaborator

Pfizer Inc.

NCT06448364

/ TerminatedPhase 1

FIRST-IN-HUMAN (FIH), OPEN-LABEL, PHASE 1 DOSE ESCALATION AND EXPANSION STUDY DESIGNED TO EVALUATE THE SAFETY, TOLERABILITY, PK, PD, AND PRELIMINARY CLINICAL ACTIVITY OF PF-07329640 AS A SINGLE AGENT OR IN COMBINATION TREATMENT FOR PARTICIPANTS WITH ADVANCED SOLID TUMORS.

The purpose of this study is to learn about the safety (the impact of the study drug on the participant's body), effects of the study drug alone or in combination with bevacizumab or sasanlimab, and to find the best dose.
This study is seeking participants who have solid tumors that:
* have advanced (cancer that doesn't disappear or stay away with treatment) or
* has spread to other parts of the body (metastatic).
This includes (but limited to) the following cancer types:
* Non-Small Cell Lung Cancer (NSCLC): It's a type of lung cancer where the cells grow slowly but often spread to other parts of the body.
* Colorectal Cancer (CRC): This is a disease where cells in the colon or rectum grow out of control.
* Urothelial Cancer (UC): This is a cancer that starts in the urinary systems.
* Melanoma: Skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control.
All participants in this study will receive the study medication (PF-07329640) as an IV infusion (given directly into a vein) at the study clinic every week for repeating 28-day cycles.
Depending on which part of the study participants are enrolled in they will receive the study medication (PF-07329640 alone or in combination with other anti-cancer medications (bevacizumab or sasanlimab). Bevacizumab is given in the clinic as IV infusion every two weeks and sasanlimab is given as a shot under the skin every 4 weeks.
Participants can continue to take the study medication (PF-07329640) and bevacizumab until their cancer is no longer responding. Participants who are taking sasanlimab may receive it for up to 2 years.
The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and effective.
Participants will be involved in this study for up to 4 years. During this time, they will have a study visit every week. After they have stopped taking the study medication (at about at 2 years) they will be followed for another two years to see how they are doing.

Start Date09 May 2024

Sponsor / Collaborator

Pfizer Inc.

NCT05601973

/ RecruitingPhase 2IIT

A Multicentre Single-arm Phase II Trial of Amivantamab, Lazertinib Plus Bevacizumab in Patients With EGFR-mutant Advanced NSCLC With Progression on Previous Third-generation EGFR-TKI

AMAZE-lung is a multicenter single-arm phase II trial. The protocol treatment consists of amivantamab, lazertinib and bevacizumab (Zirabev®), given in a three-weekly regimen. The primary objective of the trial is to assess the efficacy of amivantamab and bevacizumab added to continued treatment with the third-generation EGFR-TKI lazertinib, in patients with EGFR-mutant advanced NSCLC, who have been previously treated with a third-generation EGFR-TKI in order to provide data on treatment effect and sample size required for a future phase III trial.
In addition, the safety of the treatment combination will be evaluated.

Start Date27 Mar 2023

Sponsor / Collaborator

Janssen Pharmaceuticals, Inc.

100 Clinical Results associated with Bevacizumab-BVZR

100 Translational Medicine associated with Bevacizumab-BVZR

100 Patents (Medical) associated with Bevacizumab-BVZR

Literatures (Medical) associated with Bevacizumab-BVZR

02 Jan 2025·Expert Opinion On Drug Safety

Safety of marketed biosimilar monoclonal antibody cancer treatments in the US: a disproportionality analysis using the food and drug administration adverse event reporting system (FAERS) database

Article

Author: Xue, Xiangzhong ; Qian, Jingjing

BACKGROUND:

By 31 December 2022, the United States Food and Drug Administration (FDA) has approved 12 biosimilar monoclonal antibody cancer treatments. This study detected disproportionate adverse event (AE) reporting signals and compared safety profile of individual biosimilars to their originator biologics and between each pair of biosimilars.

RESEARCH DESIGN AND METHODS:

The FDA Adverse Event Reporting System data (6/1/2018-12/31/2022) were used to identify AE reports for rituximab, bevacizumab, trastuzumab, and their marketed biosimilars. Reporting odds ratios and empirical Bayesian geometric mean were computed to detect reporting disproportionality in serious, death, and specific AEs between studied biologics/biosimilars and all other drugs.

RESULTS:

Significant AE reporting signals were identified: 1) death for biological rituximab, pruritus for biosimilar rituximab-pvvr, and infusion-related reactions for biological rituximab and biosimilar rituximab-pvvr (significantly higher ROR for rituximab-pvvr than biological rituximab, p < .0001); 2) death for biological bevacizumab and biosimilar bevacizumab-bvzr (significantly higher ROR for bevacizumab-bvzr than biological bevacizumab, p < .0001), hypertension, platelet count decreased (PCD), and proteinuria for biological bevacizumab and biosimilar bevacizumab-awwb (significantly higher ROR of PCD for bevacizumab-awwb than originator bevacizumab, p = .001); and 3) rash for biosimilar trastuzumab-anns.

CONCLUSIONS:

Findings call for large, longitudinal studies to examine causality of certain AEs with rituximab-pvvr and bevacizumab biosimilars.

01 Dec 2024·VALUE IN HEALTH

Cost-Effectiveness Analysis of Bevacizumab Biosimilars Versus Originator Bevacizumab for Metastatic Colorectal Cancer: A Comparative Study Using Real-World Data

Article

Author: Nguyen, Lena ; Mercer, Rebecca E ; Muñoz, Caroline ; Chan, Kelvin K W ; Dvorani, Erind ; Adamic, Andrea ; Beca, Jaclyn M ; Lu, Brandon

OBJECTIVES:

MVASI (Amgen) and Zirabev (Pfizer) are 2 of the earliest bevacizumab biosimilars approved for the first-line treatment of metastatic colorectal cancer (mCRC). We aimed to confirm and quantify the real-world cost savings and cost-effectiveness of MVASI and Zirabev relative to originator bevacizumab for patients with mCRC.

METHODS:

We conducted a population-based, retrospective cohort study in Ontario, Canada, where originator and biosimilar bevacizumab are universally publicly funded. All mCRC patients who received originator bevacizumab between January 2008 and August 2019 or biosimilar bevacizumab between August 2019 and March 2021 were propensity score matched (1:4) to adjust for baseline differences. Total 1-year patient-level costs (CAD) and effects (life years [LY] and quality-adjusted LYs) were calculated from the public health payer's perspective. Primary outcomes included incremental net monetary benefit and incremental net health benefit (INHB). Sensitivity analyses included a subgroup analysis by biosimilar type (MVASI/Zirabev) and a 2-year analysis.

RESULTS:

The matched cohort included 747 biosimilar cases and 2945 comparators. Bevacizumab biosimilars were associated with an incremental cost of -$6379 (95%CI: -9417, -3537) (ie, cost saving) and incremental effect of 0.0 (95% CI: -0.02, 0.02) LY and -0.01 (95% CI: -0.03, 0) quality-adjusted LYs gained. Incremental net monetary benefit and INHB estimates were $6331 (95% CI: 6245, 6417) and 0.127 LY (95% CI: 0.125, 0.128), respectively, at a willingness-to-pay threshold of $50 000/life year gained, with all estimates indicating the cost-effectiveness of biosimilar bevacizumab. Cost-effectiveness remained consistent across biosimilar brand subgroups and 2-year sensitivity analyses.

CONCLUSION:

Bevacizumab biosimilars demonstrated real-world cost savings while providing similar survival benefit as originator bevacizumab, confirming the initial expectations of their implementation and supporting health system sustainability.

01 Nov 2024·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

In silico evaluation of corneal patch eluting anti-VEGF agents concept

Article

Author: Heljak, Marcin K ; Gunduz, Oguzhan ; Cesur, Sumeyye ; Kijeńska-Gawrońska, Ewa ; Swieszkowski, Wojciech ; Heljak, Marcin K. ; Ilhan, Elif

This study introduces a novel approach utilizing a temporary drug-eluting hydrogel corneal patch to prevent neovascularization, alongside a numerical predictive tool for assessing the release and transport kinetics of bevacizumab (BVZ) after the keratoplasty. A key focus was investigating the impact of tear film clearance on the release kinetics and drug transport from the designed corneal patch. The proposed tear drug clearance model incorporates the physiological mechanism of lacrimal flow (tear turnover), distinguishing itself from previous models. Validation against experimental data confirms the model's robustness, despite limitations such as a 2D axisymmetrical framework and omission of blink frequency and saccadic eye movements potential effects. Analysis highlights the significant influence of lacrimal flow on ocular drug transport, with the corneal patch extending BVZ residence time compared to topical administration. This research sets the stage for exploring multi-layer drug-eluting corneal patches as a promising therapeutic strategy in ocular health.

News (Medical) associated with Bevacizumab-BVZR

28 Feb 2025

·www.prnewswire.com

ACCESS MEDICAL LABS CONFIRMS ELIZABETH HOLMES EXACT PFIZER STUDY RESULTS USING THE SAME COMPONENTS

JUPITER, Fla., Feb. 28, 2025 /PRNewswire/ -- In a stunning revelation that will reshape the conversation around Elizabeth Holmes and her work at Theranos, one of the largest Specialty Labs in the Nation has confirmed that Holmes' diagnostic technology was in fact Accurate—and that her suppressed Test Result findings regarding Avastin®, a cancer drug were very accurate during the 15 month Pfizer study in 2007. In 2007 and 2008, Holmes conducted a study for Pfizer investigating the angiogenesis process and the effect of Bevacizumab, an anti-VEGF antibody therapy used in cancer treatment under the brand name, Avastin® See page 0012 of Trial exhibit 0143. – bottom half of 0012 shows the Avastin® affect. The Pfizer contract with Theranos was executed on December 12th 2006 worth $900,000.00. The study took place in clinics and in patient homes with her machine wirelessly transmitting Results to Theranos servers and the Pfizer portal during the course. Her research demonstrated that while the drug initially appeared to suppress VEGF levels, that was only true using another companies reagent that is used by LabCorp and many labs across the nation called, R&D Systems VEGF ELISA. Avastin® is a monoclonal antibody that attaches to VEGF in the body to prevent the body from making blood vessels (angiogenesis) so the cancer will not spread. The problem is, ELISA testing using Antibodies, in fact the same antibody as Avastin, Anti-VEGF or better known as Bevacizumab. This causes a problem when testing for VEGF because you cannot detect it due to the same antibody being present. It doesn't know VEGF is present, it is being blocked by Anti-VEGF. She also discovered that Avastin causes what's called a VEGF complex, which means the body starts creating TONS of VEGF. VEGF levels spiked dramatically—showing an alarming surge from an average of 140 pg/mL to over 8,000 pg/mL. This post-treatment VEGF REBOUND effect signals a rapid increase in blood vessel formation, which could exacerbate cancer proliferation rather than control it. Her study was also confirmed independently in 2023 by JAMA open network. Despite Holmes' findings, Pfizer and Dr. Shane Weber who testified against Elizabeth Holmes in court, rejected the results on December 31st 2008. Holmes' research was originally conducted using the Theranos Edison (TSPU - Theranos System Processing Unit), which ran proprietary assays to measure both free and total VEGF levels. Unlike traditional laboratory methods—which only detect unbound VEGF—the Theranos approach provided a complete picture, revealing the dangers of VEGF suppression therapy when treatment is discontinued. Holmes' Study was originally conducted using the Edison or aka the TSPU - Theranos Systems Processing Unit, which ran proprietary assays developed in house at Theranos and commercially available test kits used by Lab Giants, LabCorp and Quest. In this case of VEGF, she used her proprietary test measure both free and total VEGF levels. Unlike traditional laboratory methods—which only detect unbound VEGF—the Theranos approach provided a complete picture, revealing the dangers of VEGF suppression therapy when treatment is discontinued because she could detect the TOTAL VEGF. Today, Access Medical Labs has demonstrated that: Holmes' technology was indeed Accurate. Conventional testing methods, such as those used by LabCorp may underreport the true impact of anti-VEGF drugs. When Bevacizumab exits the bloodstream, a VEGF rebound may occur and CANNOT be detected early enough due to VEGF being blocked which could drastically increase the spread of cancer. Our lab testing proves that Elizabeth Holmes did not lie. Her tests & machine worked. Ryan ElHosseiny Access Medical Labs 954-494-1664 SOURCE Access Medical Labs WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultDiagnostic Reagents

04 Feb 2025

·pmlive.com

Pfizer announces positive phase 3 results for Braftovi regimen in colorectal cancer

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall survival in a late-stage colorectal cancer (CRC) study. The ongoing phase 3 BREAKWATER trial has been evaluating the drug in combination with Eli Lilly/Merck KGaA’s Erbitux (cetuximab) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) in patients with previously untreated BRAF V600E-mutant metastatic CRC. The Braftovi regimen demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoint of progression-free survival and the key secondary endpoint of overall survival compared chemotherapy with or without bevacizumab. Approximately 154,270 people are expected to be diagnosed with cancer of the colon or rectum in the US this year. BRAF mutations are estimated to occur in up to 12% of those with metastatic cases of the disease and are associated with a poor prognosis. Braftovi is an oral small molecule kinase inhibitor designed to target the most common BRAF mutation, BRAF V600E, which more than doubles patients’ risk of death compared to those with no known mutation present. The drug was granted accelerated approval by the US Food and Drug Administration (FDA) in December in combination with Erbitux and mFOLFOX6 for treatment-naïve patients with BRAF V600E-mutant metastatic CRC based on a clinically meaningful and statistically significant improvement in confirmed objective response rate, BREAKWATER’s other dual primary endpoint. Pfizer said it will now be sharing the new trial results with the FDA to support the potential conversion to full approval for the combination in this indication, adding that the data is also being discussed with other regulatory authorities globally. Pfizer’s chief oncology officer, Roger Dansey, said: “We are extremely pleased with the clinically meaningful progression-free survival and overall survival results from the BREAKWATER study, which have the potential to be practice-changing for this patient population that has historically had limited treatment options and poor outcomes. “The Braftovi regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with metastatic CRC with a BRAF V600E mutation. We look forward to discussing this data with global health authorities to bring this treatment to more patients around the world, as soon as possible.” Pfizer has exclusive rights to Braftovi in the US, Canada, Latin America, the Middle East and Africa, while licences are also held by Ono Pharmaceutical, Medison and Pierre Fabre.

Clinical ResultPhase 3Accelerated ApprovalDrug Approval

03 Feb 2025

·pipelinereview.com

Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial

NEW YORK, NY, USA I February 03, 2025 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI ® (encorafenib) in combination with cetuximab (marketed as ERBITUX ® ) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation. The trial showed a statistically significant and clinically meaningful improvement in PFS, one of its dual primary endpoints, as assessed by blinded independent central review (BICR) compared to patients receiving chemotherapy with or without bevacizumab. Further, the BRAFTOVI combination regimen demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint in the trial. “We are extremely pleased with the clinically meaningful progression-free survival and overall survival results from the BREAKWATER study, which have the potential to be practice-changing for this patient population that has historically had limited treatment options and poor outcomes,” said Roger Dansey, M.D., Chief Oncology Officer, Pfizer. “The BRAFTOVI regimen is emerging as a new standard of care as the first targeted therapy approved for use as early as first-line for patients with mCRC with a BRAF V600E mutation. We look forward to discussing these data with global health authorities to bring this treatment to more patients around the world, as soon as possible.” The BRAFTOVI combination regimen received accelerated approval by the U.S. Food and Drug Administration (FDA) in December 2024 for treatment-naïve patients with BRAF V600E -mutant mCRC based on a clinically meaningful and statistically significant improvement in confirmed objective response rate (ORR), the study’s other dual primary endpoint. The ORR results were presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI) and were simultaneously published in Nature Medicine in January 2025. At the time of the ORR analysis, the safety profile of BRAFTOVI in combination with cetuximab and mFOLFOX6 continued to be consistent with the known safety profile of each respective agent. No new safety signals were identified. Detailed results from this analysis will be submitted for presentation at an upcoming medical meeting. The approval of the BRAFTOVI combination regimen was among the first in the industry to be conducted under the FDA’s Project FrontRunner, which seeks to support the development and approval of new cancer drugs for advanced or metastatic disease. Pfizer will share these latest results with the FDA to potentially support full approval for BRAFTOVI in combination with cetuximab and mFOLFOX6 in patients with mCRC with a BRAF V600E mutation. The BREAKWATER data are also being discussed with other regulatory authorities around the world to support potential additional license applications for the BRAFTOVI combination regimen in this indication. About BREAKWATER BREAKWATER is a Phase 3, randomized, active-controlled, open-label, multicenter trial of BRAFTOVI with cetuximab, alone or in combination with mFOLFOX6 in participants with previously untreated BRAF V600E-mutant metastatic CRC. Patients were randomized to receive BRAFTOVI 300 mg orally once daily in combination with cetuximab (discontinued after randomization of 158 patients), BRAFTOVI 300 mg orally once daily in combination with cetuximab and mFOLFOX6 (n=236) or mFOLFOX6, FOLFOXIRI, or CAPOX each with or without bevacizumab (control-arm) (n=243). The dual primary endpoints are ORR, which was met at the time of analysis, and progression-free survival (PFS) as assessed by blinded independent central review (BICR). Overall survival is a key secondary endpoint. About Colorectal Cancer (CRC) CRC is the third most common type of cancer in the world, with approximately 1.8 million new diagnoses in 2022. 1 It is the second leading cause of cancer-related deaths. 2 Overall, the lifetime risk of developing CRC is about 1 in 24 for men and 1 in 26 for women. 2 In the U.S. alone, an estimated 154,270 people will be diagnosed with cancer of the colon or rectum in 2025, and approximately 53,000 are estimated to die from the disease each year. 3 For 20% of those diagnosed with CRC, the disease has metastasized, or spread, making it harder to treat, and up to 50% of patients with localized disease eventually develop metastases. 4 BRAF mutations are estimated to occur in 8-12% of people with mCRC and represent a poor prognosis for these patients. 5 The BRAF V600E mutation is the most common BRAF mutation and the risk of mortality in CRC patients with the BRAF V600E mutation is more than double that of patients with no known mutation present. 5,6 Despite the high unmet need in BRAF V600E -mutant mCRC, prior to December 20, 2024 there were no approved biomarker-driven therapies specifically indicated for people with previously untreated BRAF V600E -mutant mCRC. 7,8 About BRAFTOVI ® (encorafenib) BRAFTOVI is an oral small molecule kinase inhibitor that targets BRAF V600E. Inappropriate activation of proteins in the MAPK signaling pathway (RAS-RAF-MEK-ERK) has been shown to occur in certain cancers, including CRC. Pfizer has exclusive rights to BRAFTOVI in the U.S., Canada, Latin America, Middle East, and Africa. Ono Pharmaceutical Co., Ltd. has exclusive rights to commercialize the product in Japan and South Korea, Medison has exclusive rights to commercialize the product in Israel and Pierre Fabre Laboratories has exclusive rights to commercialize the product in all other countries, including Europe and Asia (excluding Japan and South Korea). INDICATION AND USAGE BRAFTOVI ® (encorafenib) is indicated, in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). BRAFTOVI is also indicated, in combination with cetuximab, for the treatment of adult patients with mCRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF CRC. View the full Prescribing Information . About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibodies, including other immune-oncology biologics. We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to help people with cancer live better and longer lives. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com . In addition, to learn more, please visit us on www.Pfizer.com and follow us on X at @Pfizer and @Pfizer News , LinkedIn , YouTube and like us on Facebook at Facebook.com/Pfizer . References SOURCE: Pfizer

Clinical ResultPhase 3ASCOLicense out/inDrug Approval

100 Deals associated with Bevacizumab-BVZR

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC07	DB00112

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glioma	Japan	Pfizer Japan, Inc.	13 Dec 2023
Ovarian Cancer	Japan	Pfizer Japan, Inc.	28 Aug 2023
Fallopian Tube Carcinoma	United States	Pfizer Inc.	09 Feb 2021
Ovarian Epithelial Carcinoma	United States	Pfizer Inc.	09 Feb 2021
Primary peritoneal carcinoma	United States	Pfizer Inc.	09 Feb 2021
Advanced Lung Non-Small Cell Carcinoma	Japan	Pfizer Japan, Inc.	23 Sep 2020
Advanced Renal Cell Carcinoma	Australia	Pfizer Australia Pty Ltd.	21 Nov 2019
Breast Cancer	Australia	Pfizer Australia Pty Ltd.	21 Nov 2019
High grade glioma	Australia	Pfizer Australia Pty Ltd.	21 Nov 2019
Metastatic Cervical Carcinoma	Australia	Pfizer Australia Pty Ltd.	21 Nov 2019
Platinum-Resistant Epithelial Ovarian Carcinoma	Australia	Pfizer Australia Pty Ltd.	21 Nov 2019
Platinum-Resistant Fallopian Tube Carcinoma	Australia	Pfizer Australia Pty Ltd.	21 Nov 2019
Platinum-Resistant Primary Peritoneal Carcinoma	Australia	Pfizer Australia Pty Ltd.	21 Nov 2019
Platinum-sensitive epithelial ovarian cancer	Australia	Pfizer Australia Pty Ltd.	21 Nov 2019
Platinum-Sensitive Fallopian Tube Carcinoma	Australia	Pfizer Australia Pty Ltd.	21 Nov 2019
Platinum-Sensitive Primary Peritoneal Carcinoma	Australia	Pfizer Australia Pty Ltd.	21 Nov 2019
Recurrent Cervical Cancer	Australia	Pfizer Australia Pty Ltd.	21 Nov 2019
Metastatic Colorectal Carcinoma	United States	Pfizer Inc.	27 Jun 2019
Metastatic Renal Cell Carcinoma	United States	Pfizer Inc.	27 Jun 2019
Non-squamous non-small cell lung cancer	United States	Pfizer Inc.	27 Jun 2019

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	China	Pfizer Biologics (Hangzhou) Co., Ltd	11 Jun 2020
Advanced Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	China	Global Life Sciences Technologies (Shanghai) Co. Ltd.	11 Jun 2020
Non-Small Cell Lung Cancer	Phase 1	China	Pfizer Biologics (Hangzhou) Co., Ltd	17 Mar 2021
Non-Small Cell Lung Cancer	Phase 1	China	Global Life Sciences Technologies (Shanghai) Co. Ltd.	17 Mar 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04325698 (CTgov)	Phase 3	Non-squamous non-small cell lung cancer	8	PF-06439535 (PF-06439535 (CN))	peoeqprxbz = dmepdirmyu pcaclznszs (ctonyejnuy, rousrwvvbe - urminssrtd) View more	-	01 Oct 2024
				Bevacizumab (Bevacizumab (EU))	peoeqprxbz = onbjbmedbz pcaclznszs (ctonyejnuy, cbblenqzwa - vtmmlwsjjj) View more
NCT02364999 (Pubmed \| Cancer Chemother Pharmacol)	Phase 3	Advanced Lung Non-Squamous Non-Small Cell Carcinoma	719	PF-06439535	balvggspav(qvmwsltnna) = dwbvblsofh bbbxkqwiow (pqatspohhh ) View more	-	01 Mar 2020
NCT02364999 (CTgov)	Phase 3	Non-squamous non-small cell lung cancer	719	Carboplatin+Paclitaxel+Bevacizumab-EU	gieyikartc = vzgedimigf nbssxsfsjn (wbeidgmtqa, tdxcndegem - rdjhagzija) View more	-	27 Jun 2018
NCT02364999 (ASCO 12018 \| ASCO 22018) Manual	Phase 3	Non-squamous non-small cell lung cancer First line	719	paclitaxel+carboplatin+PF-06439535	flptwtdlqa(vjfqlaxnzw) = mkvpfcaytm gnzlblgxyn (ybiqwraxjf, 40.01 - 50.57) View more	Similar	04 Jun 2018
				paclitaxel+carboplatin+bevacizumab	flptwtdlqa(vjfqlaxnzw) = bnqxbsivvh gnzlblgxyn (ybiqwraxjf, 39.40 - 49.89) View more
NCT02031991 (REFLECTIONS B739-01, WCLC2015)	Phase 1	First line	102	PF-06439535	ksmdxlruir(kicgqvlgbi) = dzvhfntsgq mxeczqexom (hwynfxybeh, 876)	-	07 Sep 2015
				Bevacizumab-EU	ksmdxlruir(kicgqvlgbi) = fojzktxvjt mxeczqexom (hwynfxybeh, 2260)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis